| Data show that compared with the EGFR mutant and WT/WT cohorts, patients with EML4-ALK mutant tumors were significantly younger and were more likely to be men. | Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.
Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, Solomon B, Stubbs H, Admane S, McDermott U, Settleman J, Kobayashi S, Mark EJ, Rodig SJ, Chirieac LR, Kwak EL, Lynch TJ, Iafrate AJ., Free PMC Article | 01/21/2010 |
| Genomic rearrangements accompanying the EML4-ALK fusion is associated with non-small cell lung cancer. | Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts.
Takeuchi K, Choi YL, Soda M, Inamura K, Togashi Y, Hatano S, Enomoto M, Takada S, Yamashita Y, Satoh Y, Okumura S, Nakagawa K, Ishikawa Y, Mano H. | 01/21/2010 |
| EML4-ALK fusion gene product is involved in the carcinogenesis in non-small cell lung carcinomas | EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas.
Shinmura K, Kageyama S, Tao H, Bunai T, Suzuki M, Kamo T, Takamochi K, Suzuki K, Tanahashi M, Niwa H, Ogawa H, Sugimura H. | 01/21/2010 |
| A lung cancer cell line expressing endogenous variant 3 of EML4-ALK underwent cell death on exposure to a specific inhibitor of ALK catalytic activity. | Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer.
Choi YL, Takeuchi K, Soda M, Inamura K, Togashi Y, Hatano S, Enomoto M, Hamada T, Haruta H, Watanabe H, Kurashina K, Hatanaka H, Ueno T, Takada S, Yamashita Y, Sugiyama Y, Ishikawa Y, Mano H. | 01/21/2010 |
| EML4-ALK fusion gene is expressed in lung cancer | EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.
Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits E, Holmes AJ, Choi HG, Kim J, Chiang D, Thomas R, Lee J, Richards WG, Sugarbaker DJ, Ducko C, Lindeman N, Marcoux JP, Engelman JA, Gray NS, Lee C, Meyerson M, Jänne PA., Free PMC Article | 01/21/2010 |
| EML4-ALK fusion transcript is not present in gastrointestinal or breast cancers and is specific to NSCLC. | EML4-ALK fusion transcript is not found in gastrointestinal and breast cancers.
Fukuyoshi Y, Inoue H, Kita Y, Utsunomiya T, Ishida T, Mori M., Free PMC Article | 01/21/2010 |
| EML4-ALK fusions occur in less than 3% of non-small cell lung cancers samples; EML4 and/or ALK amplifications also occur. | EML4-ALK fusion lung cancer: a rare acquired event.
Perner S, Wagner PL, Demichelis F, Mehra R, Lafargue CJ, Moss BJ, Arbogast S, Soltermann A, Weder W, Giordano TJ, Beer DG, Rickman DS, Chinnaiyan AM, Moch H, Rubin MA., Free PMC Article | 01/21/2010 |
| EML4 is part of a fusion protein linked to histological characteristics in a subset of lung neoplasms. | EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers.
Inamura K, Takeuchi K, Togashi Y, Nomura K, Ninomiya H, Okui M, Satoh Y, Okumura S, Nakagawa K, Soda M, Choi YL, Niki T, Mano H, Ishikawa Y. | 01/21/2010 |
| EML4 negative cells showed a completely modified microtubule network, indicating that EML4 is necessary for correct microtubule formation. | Human EML4, a novel member of the EMAP family, is essential for microtubule formation.
Pollmann M, Parwaresch R, Adam-Klages S, Kruse ML, Buck F, Heidebrecht HJ. | 01/21/2010 |